+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Markets for Tyrokinse Kinase Inhibitors

  • PDF Icon


  • 137 Pages
  • October 2021
  • Region: Global
  • Greystone Associates
  • ID: 5459473

Traditional cancer therapy has focused on removal or destruction of tumors cells by surgery, radiation and rather non-selective types of chemotherapy. Surgery and radiation are often effective with tumors which are localized and have not metastasized to multiple sites throughout the body. Intensive research and clinical trial activity have led to a number of targeted treatments, using novel pathways and signaling, that have achieved results representing a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. One promising area is a class of drugs known as tyrosine kinase inhibitors, which  phosphorylate specific amino acids on substrate enzymes, changes that subsequently alter signal transduction leading to downstream changes in cellular biology. This report examines and analyzes the three dozen therapeutic drugs that are defining the TKI oncology space.

What is the market share of approved TKI therapeutics?

  • What is the global supply picture for targeted TKI therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic TKI coverage across all oncology indications?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive TKI picture for the major Oncology market segments?
  • Drug treatment resources
  • Competitive therapy map
  • Clinical trial activity
  • Who are the leading competitors in the field of next-generation TKI therapeutics?

Table of Contents

  • Executive Summary
  • Biological Drug Market Dynamics
  • Targeted Oncology
  • Tyrosine Kinase Inhibitors
  • Breast Cancers
  • TKI Therapeutics - Breast Cancer (Two Approved TKIs)
  • Breast Cancers - Clinical Trial Activity
  • Breast Cancers - Market Data
  • Gastrointestinal Cancers
  • Gastric Cancer
  • Gastrointestinal Carcinoid Tumors
  • Gastrointestinal Stromal Tumors
  • TKI Therapeutics  - Gastrointestinal Cancers (Three Approved TKIs)
  • Hematology Cancers
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • TKI Therapeutics - Hematology Cancers
  • TKI Clinical Trial Activity - Hematology Cancers (Seven Approved TKIs)
  • Leukemias
  • Lymphomas
  • Myeloma
  • Hematology Cancers - Market Data
  • Lung Cancers
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
  • TKI Therapeutics - Lung Cancers (Thirteen Approved TKIs)
  • Clinical Trial Activity - Lung Cancers
  • Market Data
  • Melanoma
  • TKI Therapeutics - Melanoma (Three Approved TKIs)
  • Melanoma - Clinical Trial Activity
  • Melanoma - Market Data
  • Renal Cell Carcinoma
  • TKI Therapeutics - Renal Cell Carcinoma (Three Approved TKIs)
  • Renal Cell Carcinoma - Clinical Trial Activity
  • Renal Cell Carcinoma - Market Data
  • Thyroid Cancers
  • TKI Therapeutics - Thyroid Cancers (Five Approved TKIs)
  • Thyroid Cancers - Market Data

Companies Mentioned

  • Amgen
  • AstraZeneca
  • Array Biopharma
  • Astellas
  • BeiGene
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catalent
  • Celltrion
  • Cipla
  • Daiichi Sankyp
  • Eisai
  • Eli Lilly
  • EMD Serono
  • Genentech
  • Genzyme
  • Glaxo
  • Incyte Biosciences
  • Janssen Biotech
  • Kyowa Kirin
  • Merck Sharp & Dohme
  • Mylan GmbH
  • Novartis
  • Pfizer
  • Pierre Fabre Medicament
  • Puma Biotechnology
  • Regeneron
  • Roche
  • Samsung Bioepis
  • Sandoz
  • SeaGen
  • Takeda